Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema
Status:
Completed
Trial end date:
2017-09-27
Target enrollment:
Participant gender:
Summary
The Endurance Trial is a Phase IV open label clinical study to assess the need for ongoing
intravitreal aflibercept injections after the 3-year VISTA DME (VGFT-OD-1009) endpoint.
Subjects will be treated with intravitreal aflibercept injections pro re nata (PRN) based on
the presence of CR-DME (Clinically Relevant-DME). In addition, subjects who meet re-treatment
criteria will be eligible for focal laser treatment every 90 days